ARS Pharmaceuticals initiated with an Outperform at Scotiabank

Scotiabank analyst Louise Chen initiated coverage of ARS Pharmaceuticals (SPRY) with an Outperform rating and $30 price target The firm says it is “time to take a look” at ARS shares “ahead of tailwinds that could drive robust uptake” of its newly launched neffy, a nasal spray alternative to epinephrine injections for severe allergic reactions. The share setup is good, with a product that addresses unmet needs, an experienced management team to launch it, and a price that is more affordable than generic epinephrine injections, the analyst tells investors in a research note.